[SCHEDULE 13G] CNS Pharmaceuticals, Inc. SEC Filing
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 561,148 shares of CNS Pharmaceuticals common stock, representing 9.99% of the class. Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd. (the Master Fund), exercises shared voting and dispositive power over these shares; Mr. Boyd, as managing member of Armistice Capital, is similarly reported to have shared voting and dispositive power. The filing states the Master Fund is the direct holder and that it disclaims beneficial ownership to the extent it cannot vote or dispose of the securities under its investment management agreement.
Armistice Capital, LLC e Steven Boyd dichiarano la titolarit脿 beneficiaria di 561.148 azioni ordinarie di CNS Pharmaceuticals, pari al 9,99% della categoria. Armistice Capital, in qualit脿 di gestore degli investimenti per Armistice Capital Master Fund Ltd. (il Master Fund), esercita poteri condivisi di voto e di disposizione su tali azioni; il sig. Boyd, come socio amministratore di Armistice Capital, 猫 indicato allo stesso modo come avente poteri condivisi di voto e di disposizione. La comunicazione precisa che il Master Fund 猫 il detentore diretto e che declina la titolarit脿 beneficiaria nella misura in cui non pu貌 votare o disporre dei titoli in base al suo mandato di gestione degli investimenti.
Armistice Capital, LLC y Steven Boyd notifican la propiedad beneficiaria de 561.148 acciones ordinarias de CNS Pharmaceuticals, que representan el 9,99% de la clase. Armistice Capital, como gestor de inversiones de Armistice Capital Master Fund Ltd. (el Master Fund), ejerce poderes compartidos de voto y disposici贸n sobre estas acciones; el Sr. Boyd, como miembro gerente de Armistice Capital, figura igualmente con poderes compartidos de voto y disposici贸n. La presentaci贸n aclara que el Master Fund es el titular directo y que renuncia a la propiedad beneficiaria en la medida en que no puede votar o disponer de los valores en virtud de su acuerdo de gesti贸n de inversiones.
Armistice Capital, LLC鞕� Steven Boyd電� CNS Pharmaceuticals鞚� 氤错喌欤� 561,148欤�毳� 鞁れ 靻岇湢頃橁碃 鞛堨溂氅� 鞚措姅 頃措嫻 欤检嫕甑办潣 9.99%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頃╇媹雼�. Armistice Capital鞚� Armistice Capital Master Fund Ltd.(毵堨姢韯� 韼�霌�)鞚� 韴瀽 鞖挫毄靷靹� 鞚� 欤检嫕霌れ棎 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 頄夓偓頃橂┌, Armistice Capital鞚� 毵る媹歆� 氅る矂鞚� Boyd 鞌弰 霃欖澕頃橁矊 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃� 瓴冹溂搿� 氤搓碃霅╇媹雼�. 氤搓碃靹滌棎電� 毵堨姢韯� 韼�霌滉皜 歆侅爲 氤挫湢鞛愳澊氅�, 韴瀽 鞖挫毄瓿勳暯鞐� 霐半澕 歃濌秾鞚� 韴憸頃橁卑雮� 觳橂秳頃� 靾� 鞐嗠姅 氩旍渼鞐� 雽�頃挫劀電� 鞁れ 靻岇湢毳� 韽赴頃滊嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
Armistice Capital, LLC et Steven Boyd d茅clarent la propri茅t茅 b茅n茅ficiaire de 561 148 actions ordinaires de CNS Pharmaceuticals, repr茅sentant 9,99 % de la cat茅gorie. Armistice Capital, en tant que gestionnaire d'investissement d'Armistice Capital Master Fund Ltd. (le Master Fund), exerce des pouvoirs partag茅s de vote et de disposition sur ces actions ; M. Boyd, en tant que membre g茅rant d'Armistice Capital, est 茅galement indiqu茅 comme d茅tenant des pouvoirs partag茅s de vote et de disposition. Le d茅p么t pr茅cise que le Master Fund est le d茅tenteur direct et qu'il d茅cline la propri茅t茅 b茅n茅ficiaire dans la mesure o霉 il ne peut pas voter ou disposer des titres en vertu de son contrat de gestion d'investissement.
Armistice Capital, LLC und Steven Boyd geben an, wirtschaftlicher Eigent眉mer von 561.148 Aktien der Stammaktien von CNS Pharmaceuticals zu sein, was 9,99% der Klasse entspricht. Armistice Capital 眉bt als Investmentmanager des Armistice Capital Master Fund Ltd. (dem Master Fund) gemeinsame Stimm- und Verf眉gungsrechte 眉ber diese Aktien aus; Herr Boyd, als gesch盲ftsf眉hrendes Mitglied von Armistice Capital, wird ebenfalls mit gemeinsamen Stimm- und Verf眉gungsrechten angegeben. Die Meldung stellt fest, dass der Master Fund der direkte Inhaber ist und dass er die wirtschaftliche Eigent眉merschaft insoweit bestreitet, als er die Wertpapiere gem盲脽 seinem Investmentmanagementvertrag nicht abstimmen oder ver盲u脽ern kann.
- Clear disclosure of beneficial ownership amounting to 561,148 shares (9.99%)
- Transparency about the relationship: Armistice Capital as investment manager and the Master Fund as direct holder, with explanation of voting/dispositive authority
- None.
Insights
TL;DR: A near-10% disclosed stake by an activist-capable manager signals a meaningful position but not outright control.
Armistice's reported 9.99% position is material by percent-of-class standards and warrants attention because investment managers with shared voting power can influence governance or strategic outcomes, particularly in small-cap issuers. The filing clarifies that voting and disposition authority rests with Armistice under an investment management agreement while the Master Fund is the direct holder. This structure is common for manager-held stakes and creates potential for engagement without immediate control.
TL;DR: Disclosure is standard and complete regarding voting/dispositive authority and the manager-client relationship.
The statement clearly discloses shared voting and dispositive power and includes the Master Fund's disclaimer of direct beneficial ownership due to the investment management agreement. The joint filing and signature by the managing member satisfy Rule 13d-1(k) joint-filing conventions. From a governance perspective, this creates a notable stakeholder that could engage with the board but lacks unilateral control based on the reported stake.
Armistice Capital, LLC e Steven Boyd dichiarano la titolarit脿 beneficiaria di 561.148 azioni ordinarie di CNS Pharmaceuticals, pari al 9,99% della categoria. Armistice Capital, in qualit脿 di gestore degli investimenti per Armistice Capital Master Fund Ltd. (il Master Fund), esercita poteri condivisi di voto e di disposizione su tali azioni; il sig. Boyd, come socio amministratore di Armistice Capital, 猫 indicato allo stesso modo come avente poteri condivisi di voto e di disposizione. La comunicazione precisa che il Master Fund 猫 il detentore diretto e che declina la titolarit脿 beneficiaria nella misura in cui non pu貌 votare o disporre dei titoli in base al suo mandato di gestione degli investimenti.
Armistice Capital, LLC y Steven Boyd notifican la propiedad beneficiaria de 561.148 acciones ordinarias de CNS Pharmaceuticals, que representan el 9,99% de la clase. Armistice Capital, como gestor de inversiones de Armistice Capital Master Fund Ltd. (el Master Fund), ejerce poderes compartidos de voto y disposici贸n sobre estas acciones; el Sr. Boyd, como miembro gerente de Armistice Capital, figura igualmente con poderes compartidos de voto y disposici贸n. La presentaci贸n aclara que el Master Fund es el titular directo y que renuncia a la propiedad beneficiaria en la medida en que no puede votar o disponer de los valores en virtud de su acuerdo de gesti贸n de inversiones.
Armistice Capital, LLC鞕� Steven Boyd電� CNS Pharmaceuticals鞚� 氤错喌欤� 561,148欤�毳� 鞁れ 靻岇湢頃橁碃 鞛堨溂氅� 鞚措姅 頃措嫻 欤检嫕甑办潣 9.99%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頃╇媹雼�. Armistice Capital鞚� Armistice Capital Master Fund Ltd.(毵堨姢韯� 韼�霌�)鞚� 韴瀽 鞖挫毄靷靹� 鞚� 欤检嫕霌れ棎 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 頄夓偓頃橂┌, Armistice Capital鞚� 毵る媹歆� 氅る矂鞚� Boyd 鞌弰 霃欖澕頃橁矊 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃� 瓴冹溂搿� 氤搓碃霅╇媹雼�. 氤搓碃靹滌棎電� 毵堨姢韯� 韼�霌滉皜 歆侅爲 氤挫湢鞛愳澊氅�, 韴瀽 鞖挫毄瓿勳暯鞐� 霐半澕 歃濌秾鞚� 韴憸頃橁卑雮� 觳橂秳頃� 靾� 鞐嗠姅 氩旍渼鞐� 雽�頃挫劀電� 鞁れ 靻岇湢毳� 韽赴頃滊嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
Armistice Capital, LLC et Steven Boyd d茅clarent la propri茅t茅 b茅n茅ficiaire de 561 148 actions ordinaires de CNS Pharmaceuticals, repr茅sentant 9,99 % de la cat茅gorie. Armistice Capital, en tant que gestionnaire d'investissement d'Armistice Capital Master Fund Ltd. (le Master Fund), exerce des pouvoirs partag茅s de vote et de disposition sur ces actions ; M. Boyd, en tant que membre g茅rant d'Armistice Capital, est 茅galement indiqu茅 comme d茅tenant des pouvoirs partag茅s de vote et de disposition. Le d茅p么t pr茅cise que le Master Fund est le d茅tenteur direct et qu'il d茅cline la propri茅t茅 b茅n茅ficiaire dans la mesure o霉 il ne peut pas voter ou disposer des titres en vertu de son contrat de gestion d'investissement.
Armistice Capital, LLC und Steven Boyd geben an, wirtschaftlicher Eigent眉mer von 561.148 Aktien der Stammaktien von CNS Pharmaceuticals zu sein, was 9,99% der Klasse entspricht. Armistice Capital 眉bt als Investmentmanager des Armistice Capital Master Fund Ltd. (dem Master Fund) gemeinsame Stimm- und Verf眉gungsrechte 眉ber diese Aktien aus; Herr Boyd, als gesch盲ftsf眉hrendes Mitglied von Armistice Capital, wird ebenfalls mit gemeinsamen Stimm- und Verf眉gungsrechten angegeben. Die Meldung stellt fest, dass der Master Fund der direkte Inhaber ist und dass er die wirtschaftliche Eigent眉merschaft insoweit bestreitet, als er die Wertpapiere gem盲脽 seinem Investmentmanagementvertrag nicht abstimmen oder ver盲u脽ern kann.
FAQ
What stake in CNS Pharmaceuticals (CNSP) did Armistice Capital report?
Who holds voting and disposition authority for the reported CNSP shares?
Is the Master Fund listed as the direct holder of the CNSP shares?
Did Steven Boyd sign the Schedule 13G for CNSP?
Does the Schedule 13G indicate an intent to influence control of CNS Pharmaceuticals?
